ArticleJournal of inflammation research2026
A Novel Chronic Psoriasis Mouse Model via Optimized Imiquimod Dosing and Machine Learning Evaluation.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Scope: Imiquimod (IMQ)-induced psoriasis-like mouse models are widely used for psoriasis research, but existing methods fail to sustain disease manifestation over time. This study explores the effect of different IMQ dosing frequencies on maintaining psoriasis symptoms in mice. Methods and Results: We compared a general IMQ model (General Model) with models that used spaced dosing (D-D Model) or 5-6 doses per week (3D-D Model) over a 28-day duration. Each experimental group consisted of eight mice (n=8) to ensure statistical significance. Both the D-D and 3D-D models maintained classic pathological features of psoriasis, including immune cell accumulation in skin and sustained levels of psoriasis-related inflammatory factors in the blood, compared to the control and General Model groups. Transcriptomic analysis revealed that D-D Model and 3D-D models mice exhibited more severe psoriasis-like lesions and significantly increased expression of IL-17 and IL-23 signaling genes (IL-17A, IL-17F, S100A9) compared to the General Model. Furthermore, adjusted dosing frequencies influenced the metabolic profile, with higher regulation of TRP channels and 2-oxocarboxylic acid metabolism in the skin of D-D mice. Subsequent, Identification and validation of a conserved psoriasis biomarker signature via machine learning and cross-species analysis. Conclusion: Adjusting the dosing frequency of conventional imiquimod-induced psoriasis-like mouse models to alternate-day administration (D-D) or three days on followed by one day off (3D-D) maintained long-term psoriasis symptoms. enhancing IL-17/IL-23 signaling pathways. This modification resulted in a model exhibiting biological characteristics more closely resembling those in humans, thereby providing a more clinically relevant model for chronic psoriasis. Despite these advantages, the current model has not yet fully recapitulated the complex seasonal and cyclical nature of clinical psoriasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.